ino-1400
Biologicalexperimental
Clinical trial activity
1 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2014 (NCT02960594)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Telomerase reverse transcriptaseImmunity, active
TERT immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ino-1400
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02960594 | Phase 1 | Dec 1, 2014 | Inovio Pharmaceuticals, Mayo Clinic, Thomas Jefferson University, University of North Carolina at Chapel Hill, University of Pennsylvania, University of Pittsburgh, Wayne State University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Inovio Pharmaceuticals | For profit | 1 | 1 | 1 | 2014 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Thomas Jefferson University | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of Pennsylvania | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of Pittsburgh | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Wayne State University | Academic/Hospital | 1 | 0 | 1 | 2014 |
7 organizations
Page 1 / 1